AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02182869
Drug: Combivent® HFA inhalation aerosol
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02182869
Drug: Combivent® CFC inhalation aerosol
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01492972
Drug: Androgen Suppression Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgen suppression will begin 8 - 10 weeks prior to the start of RT for a total of 6 (+/- 2) months. Luteinizing Hormone-Releasing Hormone (LHRH) agonist therapy will consist of analogs approved by the FDA (or by Health Canada for Canadian institutions)
Trial: NCT00386126
Drug: Iron Sucrose IV 200mg, once a week, for 5 weeks
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03113448
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To apply 3-4 times per day, every day until 8 weeks then stop
Trial: NCT01009671
Drug: ART 44
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01009671
Drug: ART 50
RxNorm normalized name: FLORASTART 500mg Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00467259
Drug: Testosterone Transdermal System
RxNorm normalized name: testosterone Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone patch, 300 mcg/day, change patch twice a week for 52 weeks
Trial: NCT00467259
Drug: Placebo patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo patch, changed twice a week for 52 weeks
Trial: NCT04304807
Drug: Melatonin 20 mg
RxNorm normalized name: melatonin 20 MG
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Melatonin was given as a total dose of 20 mg via enteral route in two doses of 10 mg each with a 1 hour interval in between.
Trial: NCT04304807
Drug: Traditional antibiotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional antibiotic treatment was given to both groups with feeding intolerance according to treatment protocols by neonatal intensive care units of Ain Shams University
Trial: NCT00136318
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00426010
Drug: caffeine/placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: caffeine or placebo, either overt or covert
Trial: NCT01227655
Drug: BIA 9-1067
RxNorm normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules will be used.
Trial: NCT01227655
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: comparator
Trial: NCT01227655
Drug: Levodopa
RxNorm normalized name: Levodopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01150981
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One capsule daily for 6 weeks.
Trial: NCT03185403
Drug: Sufentanil
RxNorm normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02322398
Drug: rFSH plus rLH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150-300 IU/d rFSH plus 75-150 IU/d rLH in 2:1 ratio
Trial: NCT01825122
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02322398
Drug: hMG
RxNorm normalized name: HMG-CoA reductase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150-300 IU/d hMG
Trial: NCT02139124
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo capsule
Trial: NCT02139124
Drug: PRC-063 25 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral 25 mg capsule - active
Trial: NCT02139124
Drug: PRC-063 70 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral 70 mg capsule - active
Trial: NCT02139124
Drug: PRC-063 100 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral 100 mg capsule - active
Trial: NCT00352235
Drug: KRN7000
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03854305
Drug: PRV-6527
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment
Trial: NCT03854305
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparator
Trial: NCT00251641
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate will be supplied as 2.5 mg tablets. Subjects are to take 15 mg/week orally for the first 6 weeks of the study. Subjects will be advised to take their MTX as a single dose (weekly) on the same day of the week. If subjects randomized to MTX 15 mg/week experience a \<25% reduction in PASI score at Week 6 (Visit 4) as compared with Baseline, their MTX dose will be increased to 20 mg/week. Subjects will be treated for 22 weeks.
Trial: NCT01348984
Drug: transdermal fentanyl patch
RxNorm normalized name: fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: TFP = transdermal fentanyl patch (50 microgram/hour)
Trial: NCT01348984
Drug: placebo patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: group 2 = placebo patch
Trial: NCT03253250
Drug: ETV；TDF；ADV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NAs
Trial: NCT01981499
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets
Trial: NCT00772720
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo BID for 7 days
Trial: NCT03482167
Drug: Niagen®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg capsules (4 capsules daily)
Trial: NCT00864266
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard cisplatin-based chemotherapy in agreement with the ELCWP guidelines (available on the website www.elcwp.org)
Trial: NCT01949168
Drug: Victrelis® (boceprevir) 800mg by mouth, TID (200 mg tablets)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01949168
Drug: Peg-Intron® (peginterferon-α-2b), 1.5ug/kg sc injection
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01949168
Drug: Rebetol® (ribavirin), 1000/1200mg by mouth daily
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02044549
Drug: Syntometrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uterotonins
Trial: NCT04158336
Drug: ZN-c3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZN-c3 is a study drug
Trial: NCT00975286
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self administered by subcutaneous injections once daily within the hour preceding breakfast.
Trial: NCT00621036
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02080832
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo daily for 8 weeks
Trial: NCT00043537
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00043537
Drug: Pill Placebo
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01674647
Drug: Vitamin K antagonist (VKA)
RxNorm normalized name: Vitamin K antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VKA orally once daily titrated to a target international normalized ratio (INR) of 2.5 (range 2.0-3.0, inclusive); the VKA type (eg, warfarin, acenocoumarol, phenprocoumon, fluindione, etc) will be assigned by the investigator according to local treatment standards
Trial: NCT03697265
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous (SC) adminstration
Trial: NCT01490866
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 400 mg/m2 Days 1 and 15; IV
Trial: NCT01524913
Drug: Corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1cc celestone (6 mg/cc) will be injected into the joint space
Trial: NCT00005823
Drug: tretinoin
RxNorm normalized name: Tretinoin
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03822364
Drug: 009-2
RxNorm normalized name: Flumist 2009-2010 Formula Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled apomorphine via Staccato aerosol, Dose 2
Trial: NCT00195013
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 grams three times a day (orally) for four days and then stop
Trial: NCT01606059
Drug: DW-0920
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage form: Extended release tablet Dosage: 2 tablets
Trial: NCT01606059
Drug: DW-0919
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage form: Extended release tablet Dosage: 1 tablet
Trial: NCT02728752
Drug: Octagam 10%
RxNorm normalized name: Octagam 10% Solution for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients to be treated with Octagam 10%
Trial: NCT01181271
Drug: Cyclophosphamide (conditioning for AUTO transplant)
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide 60 mg/kg IV bolus QD on days -3 and -2. The total daily dose of cyclophosphamide will be 60 mg/kg.
Trial: NCT04744142
Drug: Ketone supplementation
RxNorm normalized name: Ketonal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects receive either placebo or ketone ester supplementation
Trial: NCT01181271
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate will be administered once daily on days 1, 3, and 6 as an IV bolus over 15 minutes at a dose of 5 mg/m2
Trial: NCT04054128
Drug: Heparin Sodium, 1000 Units/mL Injectable Solution 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin for catheter lock: 1000 u/mL heparin solution will be used for catheter lock in both catheter lumens as standard treatment, 1.9 mL in each catheter lumen will be infused after hemodialysis treatment during 3 months.
Trial: NCT02182128
Drug: BIBF 1120
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04668976
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Please see Detailed Description.
Trial: NCT04668976
Drug: Anti-EGFR (Panitumumab or Cetuximab)
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Please see Detailed Description.
Trial: NCT01794975
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02079168
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01565265
Drug: Pergoveris in long protocol with GnRH agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ovarian hyperstimulation with recombinant FSH and recombinant FSH Ovulation induction with recombinant HCG Oocyte collection for ICSI
Trial: NCT00869986
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous, once every six months for 15 months
Trial: NCT00378716
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00378716
Drug: uracil
RxNorm normalized name: uracil
DrugBank: Uracil (DB03419)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04336124
Drug: CVM-1118 Extended-Release (ER) Capsules (200 mg/capsule)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive initial dose regimen: 400 mg of CVM-1118 ER Capsule per day (200 mg BID) in a 28-day cycle for 4 cycles.~Dose escalates from 400, 600, 800, to 1200 mg of CVM-1118 ER capsules with either BID or TID dosing.~A single-patient cohort per dose level (accelerated titration design) will be applied to the first two cohorts, 400 and 600 mg daily, and followed by the conventional 3+3 dose escalation design from the dose level of 800 mg/day.~If 2 or more patients experience a DLT, no further dose escalation will occur.
Trial: NCT00695435
Drug: TOBRADEX Ophthalmic Suspension
RxNorm normalized name: Tobradex Ophthalmic Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TOBRADEX Ophthalmic Suspension 1 drop each eye at baseline
Trial: NCT00695435
Drug: Tobramycin 0.3% / Dexamethasone 0.05% Ophthalmic Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tobramycin 0.3% / Dexamethasone 0.05% Ophthalmic Suspension 1 drop each eye at baseline
Trial: NCT00695435
Drug: TOBREX Ophthalmic Solution
RxNorm normalized name: Tobrex Ophthalmic Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TOBREX Ophthalmic Solution 1 drop each eye at baseline
Trial: NCT00750308
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo matching ramipril
Trial: NCT00750308
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo matching tadalafil
Trial: NCT02646449
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gelatin capsules Placebo capsules, identical to mirtazapine capsules, 1 capsule every a.m. Medication will be increased by one capsule to 2 capsules at Week 2, barring any side effects.
Trial: NCT00038610
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 300 mg/m\^2 by vein every 12 hours for 6 doses days 1, 2, 3 (total dose 1800 mg/m\^2) for courses 1, 3, 5, 7.
Trial: NCT00038610
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg/m\^2 by vein on day 4 after last dose of CTX for courses 1, 3, 5, 7.
Trial: NCT00038610
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 12 mg intrathecally (6 mg if via Ommaya reservoir) day 2 for courses 1, 3, 5, 7.~200 mg/m\^2 by vein over 2 hours followed by 800 mg/m\^2 over 22 hours on day 1 of courses 2, 4, 6, 8.
Trial: NCT03340870
Drug: Sonazoid™
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single Dose of Sonazoid™ lipid-stabilised aqueous suspension of perfluorobutane (PFB) gas microbubbles.
Trial: NCT03864042
Drug: caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: taken orally
Trial: NCT03864042
Drug: rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: taken orally
Trial: NCT04455178
Drug: Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: spironolactone 20mg once daily, up-titrated to 40mg once daily at 4-week or 8-week visit
Trial: NCT04455178
Drug: Indapamide
RxNorm normalized name: Indapamide
DrugBank: Indapamide (DB00808)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: indapamide 1.5mg once daily, up-titrated to 3mg once daily at 4-week or 8-week visit
Trial: NCT01518166
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as a subcutaneous injection. Given as daily volume of 100 mcl, 200 mcl and 300 mcl respectively
Trial: NCT01940497
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive doxorubicin in doses according to the locally-approved regimen q3w (1 cycle), for 4 cycles prior to initiation of trastuzumab treatment.
Trial: NCT02707861
Drug: Optimized Background Regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An investigator-selected, standard-of-care combination regimen of antiretroviral agents for treating HIV-1 infection, selected based upon patient treatment history and the results of previous viral resistance testing. The combination must contain at least one agent other than ibalizumab to which the patient's virus is sensitive (susceptible).
Trial: NCT02494102
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02196740
Drug: Metronidazole-Ciprofloxacin gatifloxacin-Clindamycin paste
RxNorm normalized name: ciprofloxacin and metronidazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulp removal,Root canal irrigation and disinfection,
Trial: NCT00004135
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00116519
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03639519
Drug: Ascorbic Acid 500Mg Chew Tab
RxNorm normalized name: ASCORBIC ACID 500MG CHEW TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ascorbic acid will be administered at the night before surgery and will be continued for five days
Trial: NCT00511667
Drug: MK0941
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK0941 10 mg, 20 mg, 30 mg, or 40 mg before each meal or before 2 meals each day, or 60 mg before 2 meals each day
Trial: NCT00511667
Drug: Comparator: Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 10 mg, 20 mg, 30 mg, or 40 mg before each meal or before 2 meals each day, or 60 mg before 2 meals each day
Trial: NCT02489019
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl is a synthetic opioid analgesic that will be used as the experimental intervention in this trial
Trial: NCT00448136
Drug: 5 FU
RxNorm normalized name: i5 Functional Food Nutritional Powder for Suspension (Vanilla Delight)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400mg/m2/day iv on days 1-5 every 6 weeks
Trial: NCT00554775
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WBRT plus matched placebo for the same schedule and duration as erlotinib hydrochloride
Trial: NCT00266357
Drug: Placebo / Duration of Treatment: 2 days for screening period
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02987920
Drug: Placebo - Concentrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Additional medication to perioperative analgesic regimen to Group A
Trial: NCT02987920
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal analgesic regimen to Group A and Group B
Trial: NCT03218163
Drug: MEDI-551 Maintenance
RxNorm normalized name: Medi-Lyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cycle 1 - Days 1, 8, 15, and 22: 4mg/kg IV Cycles 2-12 - Day 1: 4mg/kg IV
Trial: NCT00004734
Drug: pyridoxine
RxNorm normalized name: PYRIDOXINE
DrugBank: Pyridoxine phosphate (DB02209)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00004734
Drug: folic acid multivitamin
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02299817
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02987920
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multimodal analgesic regimen to Group A and Group B
Trial: NCT02987920
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multimodal analgesic regimen to Group A and Group B
Trial: NCT04461119
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral capsules for 4 weeks of treatment
Trial: NCT01876550
Drug: Mupirocin Calcium Cream, 2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mupirocin Calcium Cream, 2% (Taro Pharmaceuticals Inc.) applied topically 3 times per day for 10 consecutive days.
Trial: NCT01876550
Drug: Bactroban® Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bactroban® Cream (mupirocin calcium cream, 2%) (GlaxoSmithKline) applied topically 3 times per day for 10 consecutive days.
Trial: NCT00427713
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03606876
Drug: BAT1806 injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each subject will receive single intravenous drip of 4 mg/kg BAT1806 Injection or Actemra® (EU-licensed and US-licensed).
Trial: NCT03433755
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered per pre-filled auto-injector pen (AI/Pen). Participants will receive placebo every 2 weeks or monthly subcutaneously.
Trial: NCT01850095
Drug: dorspirenone/ethynil estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04223778
Drug: DOR/ISL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A FDC of 100 mg DOR/ 0.75 mg ISL taken in tablet form, orally, once daily
Trial: NCT04612517
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo; corresponding volume
Trial: NCT01224028
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT04082728
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in the placebo group will be instructed to take a placebo orally three times a day for four days. All patients will be instructed to take ibuprofen 600 mg orally three times a day for four days and 1000 mg paracetamol orally four times a day during the entire study period.
Trial: NCT05173246
Drug: JS001
RxNorm normalized name: Janus Kinase Inhibitor JS001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JS001 240mg, ivdrip, d1, Q3w
Trial: NCT01369017
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of NS
Trial: NCT00003034
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV